Aptima HPV Genotyping Validated for Head & Neck Squamous Cell Carcinoma

In August of 2016, the Tulsa Medical Lab Molecular Department completed validation studies to apply the Hologic Aptima HPV Genotyping Assay to head and neck fine needle aspiration samples.

Head and neck cancer is the 6th most common cancer worldwide with over 550,000 new cases each year. 90% of head and neck cancers are squamous cell carcinoma.

Currently, 72% of the oropharyngeal squamous cell carcinomas in the United States are HPV-related. HPV 16 is responsible for 90 to 95% of those cancers. Experts agree that E6/E7 detection of mRNA transcripts is generally regarded as the gold standard for HPV detection.

The Aptima HPV Genotyping Assay targets the E6/E7 mRNA of HPV 16 and 18/45 which makes it a superlative choice for determining the presence of HPV 16 in fine needle aspiration samples.

The 5 year survival rate for patients with HPV positive squamous cell carcinoma is greater than 80% comparted to 40% for patients with HPV negative head and meck squamous cell carcinoma.

For more information on this exciting and affordable test, please contact the molecular department at 918-481-7857.